Gennova Biopharma seeks DCGI nod for its Omicron booster

Gennova has developed an Omicron specific vaccine GEMCOVAC-OM which has been assessed for its safety and immunogenicity when administered as a booster in participants who have received two doses of Covishield and Covaxin, the two main Covid-19 vaccines used in the immunisation drive.

from Latest Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/tlximDW
https://ift.tt/a12AYR0

Post a Comment

Previous Post Next Post